Zacks Investment Research upgraded shares of Corindus Vascular Robotics Inc. (NYSEMKT:CVRS) from a sell rating to a hold rating in a research report report published on Tuesday.

According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “

Separately, B. Riley initiated coverage on Corindus Vascular Robotics in a research report on Thursday, October 6th. They issued a buy rating and a $3.00 price target on the stock.

Corindus Vascular Robotics (NYSEMKT:CVRS) opened at 0.9999 on Tuesday. The company’s 50-day moving average price is $1.15 and its 200-day moving average price is $1.24. Corindus Vascular Robotics has a 12-month low of $0.73 and a 12-month high of $3.50. The firm’s market capitalization is $118.93 million.

Corindus Vascular Robotics (NYSEMKT:CVRS) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.01. Equities analysts expect that Corindus Vascular Robotics will post ($0.25) EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP raised its position in shares of Corindus Vascular Robotics by 16.4% in the first quarter. Wellington Management Group LLP now owns 12,052,063 shares of the company’s stock valued at $11,937,000 after buying an additional 1,696,393 shares during the period. State Street Corp raised its position in shares of Corindus Vascular Robotics by 16.7% in the first quarter. State Street Corp now owns 230,500 shares of the company’s stock valued at $226,000 after buying an additional 32,954 shares during the period. Schwab Charles Investment Management Inc. raised its position in shares of Corindus Vascular Robotics by 236.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 84,000 shares of the company’s stock valued at $121,000 after buying an additional 59,000 shares during the period. GAM Holding AG raised its position in shares of Corindus Vascular Robotics by 5.7% in the second quarter. GAM Holding AG now owns 1,060,920 shares of the company’s stock valued at $1,522,000 after buying an additional 57,239 shares during the period. Finally, BlackRock Institutional Trust Company N.A. raised its position in shares of Corindus Vascular Robotics by 69.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 350,812 shares of the company’s stock valued at $502,000 after buying an additional 143,544 shares during the period.

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc designs, manufactures and sells precision vascular robotic-assisted systems for use in interventional vascular procedures (the CorPath System). The Company operates through the development, marketing and sales of robotic-assisted vascular interventions segment. The Company’s product, the CorPath 200 System, is a vascular robotic system, which is engaged in stent placement in percutaneous coronary intervention (PCI) procedures.

Receive News & Stock Ratings for Corindus Vascular Robotics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc. and related stocks with our FREE daily email newsletter.